Piper Jaffray Companies reissued their hold rating on shares of Inogen, Inc (NASDAQ:INGN) in a research report sent to investors on Tuesday morning. Piper Jaffray Companies currently has a $90.00 price objective on the medical technology company’s stock.

INGN has been the topic of a number of other reports. Needham & Company LLC lowered their price objective on shares of Inogen from $108.00 to $96.00 and set a strong-buy rating on the stock in a research note on Thursday, June 8th. BidaskClub cut shares of Inogen from a strong-buy rating to a buy rating in a research note on Monday, July 31st. Zacks Investment Research cut shares of Inogen from a strong-buy rating to a hold rating in a research note on Tuesday, August 8th. Finally, J P Morgan Chase & Co increased their price objective on shares of Inogen to $102.00 and gave the company an overweight rating in a research note on Monday, June 26th. Four investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $91.33.

Shares of Inogen (NASDAQ:INGN) traded down 1.9497% during mid-day trading on Tuesday, hitting $101.5703. 128,696 shares of the stock traded hands. Inogen has a 12-month low of $50.24 and a 12-month high of $104.88. The firm has a market cap of $2.11 billion, a price-to-earnings ratio of 88.1687 and a beta of 1.02. The firm’s 50 day moving average price is $95.76 and its 200 day moving average price is $87.16.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Thursday, August 3rd. The medical technology company reported $0.38 EPS for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.10. The firm had revenue of $64.10 million for the quarter, compared to analysts’ expectations of $59.99 million. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The firm’s revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.25 EPS. On average, equities research analysts predict that Inogen will post $1.21 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Inogen, Inc (INGN) Earns Hold Rating from Piper Jaffray Companies” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/09/15/inogen-inc-ingn-earns-hold-rating-from-piper-jaffray-companies.html.

In related news, EVP Matt Scribner sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $94.21, for a total value of $235,525.00. Following the transaction, the executive vice president now owns 4,833 shares in the company, valued at $455,316.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Raymond Huggenberger sold 14,000 shares of the firm’s stock in a transaction that occurred on Friday, July 14th. The shares were sold at an average price of $92.96, for a total transaction of $1,301,440.00. Following the completion of the transaction, the director now owns 7,808 shares in the company, valued at approximately $725,831.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,667 shares of company stock worth $4,170,776. Insiders own 5.31% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. purchased a new position in Inogen in the first quarter valued at approximately $109,000. Schroder Investment Management Group purchased a new position in Inogen in the second quarter valued at approximately $132,000. Victory Capital Management Inc. raised its holdings in Inogen by 36.1% in the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock valued at $134,000 after buying an additional 459 shares during the period. Sei Investments Co. raised its holdings in Inogen by 38.1% in the second quarter. Sei Investments Co. now owns 1,606 shares of the medical technology company’s stock valued at $153,000 after buying an additional 443 shares during the period. Finally, Jane Street Group LLC purchased a new position in Inogen in the first quarter valued at approximately $203,000.

Inogen Company Profile

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

Analyst Recommendations for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.